We repositioned and re-launched an established prostate cancer brand in the EMEA region, to stave off increasing competition and confirm leadership status across two indications.
We conducted qualitative research with stakeholders to validate behaviour drivers behind prescription choice.
We conducted competitive intelligence and business planning workshops, which helped inform a new positioning using existing and new data.
We produced bold and distinctive creative that worked across channels and EMEA territories; communicating clinical and emotional dimension to the brand.
We created an asset library containing all marketing materials, with localisation guidance.
We staged a high-energy internal event for sales teams to launch the new campaign, brand positioning, messaging and strategy.